Swiss Orphan Drug Status for cutaneous T-cell lymphoma drug
The Swiss Agency for Therapeutic Products (SwissMedic) has granted Orphan Drug Status (ODS) to 4SC’s Kinselby (resminostat) for the treatment of cutaneous T-cell lymphoma (CTCL). In Switzerland, ODS provides privileged status to drugs that show promise for the treatment of rare diseases and qualifies 4SC for… Read More